Strumento inattivo

Azioni Tobira Therapeutics Inc

Azioni

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

TOBIRA fait gagner plus de 40 000 euros à un investisseur !	26/10/16
Tobira Therapeutics : Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting	20/10/16
Tobira Therapeutics : Announces Presentations Related to Cenicriviroc’s Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting	03/10/16
TBRA Brower Piven Commences An Investigation Into The Proposed Sale Of Tobira Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	21/09/16
Tobira Therapeutics : Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH	20/09/16

Dirigenti	Titolo	Età	Da
Robert Michael CEO	Chief Executive Officer	53	-
Scott Reents DFI	Director of Finance/CFO	57	-
Jennifer M. Lagunas SEC	Corporate Secretary	-	-

Settore

	Variaz. 1 gen.	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2,31%	103 Mrd
REGENERON PHARMACEUTICALS, INC.	+0,56%	95,28 Mrd
ARGENX SE	+1,69%	22,15 Mrd
BIONTECH SE	-17,37%	21,02 Mrd
GENMAB A/S	-9,30%	18,15 Mrd
WUXI APPTEC CO., LTD.	-41,01%	16,74 Mrd
BEIGENE, LTD.	-14,85%	16,05 Mrd
NEUROCRINE BIOSCIENCES, INC.	+3,21%	13,68 Mrd
SAREPTA THERAPEUTICS, INC.	+33,54%	12,17 Mrd